Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HAE stock price vs DGX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DGX's multiple
Needs DGX P/E.
Implied fair value · at HAE's multiple
Needs HAE P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · DGX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Capital structure 81% equity / 19% debt · EV / Revenue 2.89x · EV / EBITDA 14.81x
DGX carries the larger enterprise value at $31.93B against $5.68B; DGX trades on the lower EV / Revenue multiple (2.89x vs 4.26x); DGX on the lower EV / EBITDA (14.81x vs 21.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Quest Diagnostics Inc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.56x
0.86x
Net debt / EBITDA
Leverage against operating earnings
3.80x
2.67x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$420.00M
Total debt
Interest-bearing obligations outstanding
$1.24B
$6.18B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BECTON DICKINSON & CO
HAE vs BDX
BAXTER INTERNATIONAL INC
HAE vs BAX
LivaNova PLC
HAE vs LIVN
STERIS plc
HAE vs STE
ABBOTT LABORATORIES
HAE vs ABT
DANAHER CORP /DE/
HAE vs DHR
THERMO FISHER SCIENTIFIC INC.
HAE vs TMO
HCA Healthcare, Inc.
HAE vs HCA
LABCORP HOLDINGS INC.
HAE vs LH
WEST PHARMACEUTICAL SERVICES INC
HAE vs WST
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
